# Pilot Feasibility

> **NIH NIH U54** · CINCINNATI CHILDRENS HOSP MED CTR · 2021 · $97,958

## Abstract

Project Summary (Pilot-Feasibility Core)
This renewal application aims to continue research on rare eosinophilic gastrointestinal diseases with a focus
on eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), eosinophilic gastroenteritis (EGE), and eosinophilic
colitis (EC) through the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). CEGIR aims
to advance the diagnosis, management, and treatment of these rare diseases. CEGIR will promote highly
collaborative, multi-site, patient-centric, translational and clinical research with the intent of addressing unmet
clinical trial readiness needs. The Pilot-Feasibility Core will support new ideas that have potential to create and/or
change paradigms concerning EoE, EG, EGE, and EC. We plan to support at least two Pilot-Feasibility Clinical
Research Projects during the course of this funding award. The Pilot-Feasibility Clinical Research Projects will
last up to two years and ideally take maximum advantage of additional resources and/or data emerging through
CEGIR. The projects will be collaborative among investigators within one or more CEGIR sites or with
investigators outside the CEGIR environment. We aim to develop a selection process that 1) enables the testing
of the most exciting and potentially novel hypotheses to develop proof-of-principle data that supports or refutes
the new idea; 2) takes optimum advantage of the CEGIR and at the same time provides an opportunity for the
participation of outside groups; 3) optimizes the chances of success of the identified projects; and 4) reports on
the progress and discoveries made. We have already identified a series of exciting, cutting-edge ideas that could
become Pilot-Feasibility Clinical Research Projects, and a process for optimally identifying, selecting, and
carrying out these projects is described.
In summary, this Pilot-Feasibility Core will financially, administratively, and scientifically support competitively
selected projects that will provide foundational data for novel, paradigm-shifting clinical interventions and clinical
trial readiness unmet needs for the rare eosinophilic diseases EoE, EG, EGE, and EC.

## Key facts

- **NIH application ID:** 10242131
- **Project number:** 5U54AI117804-08
- **Recipient organization:** CINCINNATI CHILDRENS HOSP MED CTR
- **Principal Investigator:** Ikuo Hirano
- **Activity code:** U54 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $97,958
- **Award type:** 5
- **Project period:** 2014-08-15 → 2024-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10242131

## Citation

> US National Institutes of Health, RePORTER application 10242131, Pilot Feasibility (5U54AI117804-08). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10242131. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*